Instructions for Reamberin (Meglumine sodium succinate)
Release form
Dr. D/Info 1.5%: containers polymer 250 ml 5, 10 or 32 pcs., 500 ml 5, 10 or 20 pcs.
Dr. D/Info 1.5%: booth. 200 ml or 400 ml 1 pc.
Description
The infusion solution is transparent, colourless.
1 l
sodium meglumine succinate 15g
Auxiliary substances: sodium chloride - 6 g, potassium chloride - 0.3 g, magnesium chloride hexahydrate (in terms of anhydrous) - 0.12 g, sodium hydroxide - 1.788 g, amber acid - up to pH from 6.0 to 7.0, water d/i - up to 1 l.
Ion composition per 1 l: sodium - 147 mmol, potassium - 4.02 mmol, magnesium - 1.26 mmol, chlorides - 109 mmol, succinates - 46 mmol, meglumine - 44.7 mmol.
Theoretical osmolarity 353 mOsm/l.
250 ml - multilayer polyolefin film containers (5) - group carton.
250 ml - multilayer polyolefin film containers (10) - group carton.
500 ml - multilayer polyolefin film containers (5) - group carton.
500 ml - multilayer polyolefin film containers (10) - group carton.
250 ml - multilayer polyolefin film containers (32) - group carton (for stationary).
500 ml - multilayer polyolefin film containers (20) - group carton (for stationary).
ATC codes
B05BB Solutions affecting water-electrolyte balance
Clinical-pharmacological groups / Group affiliation
Disinfectant preparation for parenteral administration
Active substance:
sodium meglumine succinate
Pharmacotherapy group
Solutions affecting water-electrolyte balance
Storage Conditions:
The drug Reamberin should be stored in a place inaccessible to children, protected from light at a temperature not higher than 25 ° C; freezing is allowed.
Best before date
The shelf life of the drug Reamberin in glass bottles is 5 years, in polymer containers - 3 years. Do not apply after the expiry date indicated on the package.
Pharmacological effect:
It has an antihypoxic and antioxidant effect, having a positive effect on aerobic processes in the cell, reducing the production of free radicals and restoring the energy potential of cells.
The preparation activates the enzymatic processes of the Krebs cycle and promotes the utilization of fatty acids and glucose by cells, normalizes the acid-alkaline balance and the gas composition of the blood. It has a moderate diuretic effect.
Testimony:
as an antihypoxic and detoxifying agent in the case of acute endogenous and exogenous intoxications of various etiology in adults and children since the age of 1.
Method of use, course and dosage
Adults: they are administered in/in a drip at a rate of 1-4.5 ml/min (up to 90 caps/min). The average daily dose is 10 ml/kg. The course of therapy - up to 11 days.
Children from 1 year: administered in a drip rate of 6-10 ml/kg/day at a rate of 3-4 ml/min. The course of therapy is 11 days.
No studies have been conducted in elderly patients. Therefore, the use of the drug Reamberin should start at a slower rate of administration: 20-40 drops/min (1-2 ml/min).
No studies were conducted in patients with renal failure. Therefore, caution is advised when administering the drug Meglumine sodium succinate in such patients.
If a decompensated alkaloz is detected, the use of the preparation should be stopped before the blood acid-alkali state is normalized.
Overdose:
No overdose information is available.
Drug interaction
The drug Reamberin is well combined with antibiotics, water-soluble vitamins, glucose solution.
It is not recommended to mix the drug Meglumine sodium succinate in a bottle or container with other drugs.
It is not allowed to introduce Reamberin® at the same time as calcium preparations due to possible deposition of calcium succinate
Use in pregnancy and breastfeeding
The drug Meglumine sodium succinate is contraindicated in pregnancy and during breastfeeding due to the lack of clinical research in these groups of patients.
Side Effect:
If the drug Meglumine sodium succinate is administered quickly, undesirable effects may occur. According to WHO, undesirable effects are classified according to their frequency as follows: very often (≥1/10); frequently (≥1/100 to <1/10); infrequently (from ≥1/1000 to <1/100); rarely (≥1/10000 to <1/1000); very rarely (<1/10000); frequency is unknown (frequency cannot be determined based on available data).
From the immune system Reamberin: Very rarely - allergic reactions, angioneurotic edema, anaphylactic shock.
From the skin and subcutaneous tissues: very rarely - allergic rash, urticaria, itching.
From the respiratory system: Very rarely - shortness of breath, dry cough.
On the cardiovascular side: Very rarely - tachycardia, heartbeat, shortness of breath, heart pain, chest pain, arterial hypotension/hypertension, short-term reactions in the form of burning sensation and redness of upper body.
On the digestive side: Very rarely - nausea, vomiting, metallic taste in mouth, abdominal pain, diarrhea.
From the nervous system: Very rarely - dizziness, headache, convulsions, tremors, paresthesia, agitation, anxiety.
Common disorders and irregularities in the site of administration: Very rarely - hyperthermia, chills, sweating, weakness, pain in the place of introduction, edema, hyperemia, phlebitis.
In order to avoid undesirable effects, it is recommended to observe the dosage mode and the rate of administration of the drug Meglumine sodium succinate.
In case of adverse reactions, it is recommended to reduce the rate of drug Meglumine sodium succinate administration.
If any of the unwanted effects specified in the instructions are aggravated or any other undesirable effects not specified in the instructions are noted, the patient should inform the doctor.
Contraindications for use:
A condition after a traumatic brain injury accompanied by swelling of the brain;
acute renal failure;
chronic kidney disease (stage 5, SCF less than 15 ml/min);
pregnancy;
Breastfeeding period;
individual intolerance.
With caution, the drug Meglumine sodium succinate should be used for alkaloza, kidney failure.
Special Instructions:
Due to the activation of aerobic processes in the body by the drug Meglumine sodium succinate, it is possible to reduce the concentration of glucose in the blood, the appearance of an alkaline reaction of urine. For diabetics or patients with reduced glucose tolerance, periodic blood glucose monitoring is required.
If the color of the solution changes or there is a residue, the use of the preparation is unacceptable.
Influence on the ability to control vehicles and machinery
It is not recommended to drive vehicles and work with mechanisms during the course of treatment with Reamberin®.
Application for kidney disorders
It is contraindicated in acute renal failure, chronic kidney disease (stage 5, SCF less than 15 ml/min).
Caution is advised when using the drug Meglumine sodium succinate in patients with kidney failure.
Terms of Sale
The drug Reamberin is prescription.
Application in elderly patients
In older patients, the drug should be administered at a slower rate.
Use in children
The drug Meglumine sodium succinate is prescribed to children over 1 year of age.
Nosology Reamberin (ICD codes)
A04.9
Bacterial intestinal infection unspecified
A05.9
Bacterial food poisoning unspecified
A40
Streptococcal sepsis
A41
Other sepsis
B34.9
Viral infection unspecified
C80
Malignant neoplasm without localization
D36.9
Benign neoplasm of unspecified localization
E88.9
Metabolism violation unspecified
J15
Bacterial pneumonia not classified elsewhere
J85
Abscess of the lung and mediastinum
J86
Piothorax (Pleura Empirical)
K65.0
Acute peritonitis (including abscess)
K70
Alcoholic liver disease
K71
Toxic liver failure
K72
Liver failure not classified in other rubrics (including hepatic coma, hepatic encephalopathy)
N73.5
Pelvic peritonitis in women unspecified
O08.0
Genital and pelvic infections caused by abortion, ectopic and molar pregnancy
O85
Postpartum sepsis
T14.9
Injury unspecified
T30
Thermal and chemical burns of unspecified location
T50.9
Other and unspecified drugs, medicines and biological substances
T65
Toxic effects of other and unspecified substances
T79.3
Post-traumatic wound infection not classified elsewhere
Z51.8
Other refined medical care
